Our GWAS analysis revealed 43 SNPs that were signifi cantly associated with pac

In the DASISION, superficial edema was much less fre quent with dasatinib compared with imatinib, and rates of grade 3 4 superficial edema were low, In the MDACC study of dasatinib, edema was reported in 32% of patients, In the オーダー ARN-509 ENESTnd trial, different types of edema were reported separately. In the nilotinib 300 mg BID, nilotinib 400 mg BID, and imatinib arms, periph eral edema occurred in 5% vs 5% vs 14%, eyelid edema occurred in 1% vs 2% vs 13%, and periorbital edema occurred in 1% vs 1% vs 12%, In the GIMEMA trial, peripheral edema was reported in 4% of patients receiving nilotinib and all cases were grade 1 2, Data for edema were not reported in the MDACC study of nilotinib, Pleural effusion Pleural effusion is rare with nilotinib and imatinib but is a more prominent side effect of dasatinib treatment, In the DASISION trial, 10% of patients in the dasatinib arm had a pleural effusion whereas no patient receiving imatinib reported this AE.<br><br> Dasatinib associated pleural effusion was grade 1 in 2% and grade 2 in 8% of patients, with no pleural effusion grade 3 or above. The occurrence of pleural effusion did not affect the efficacy of dasatinib, as shown by CCyR being achieved in 24 26 patients who had a pleural effusion. In the purchase AUY922 DASI SION trial, pleural effusion was managed using dose adjustments and or medical intervention, including dose interruption in 19 patients, diuretics in 12 patients, dose reduction in eight patients, corticosteroids in seven patients, and therapeutic thoracentesis in one patient.<br><br> Discontinuation due to pleural effusion occurred in three patients, In the MDACC study of first line dasatinib, the rate of pleural effusion was similar to DASISION, and one case of grade 3 4 pleural effusion was reported. Alisertib 分子量 Pleural effu sion occurred less frequently in patients who received dasatinib 100 mg QD compared with 50 mg BID, and two patients discontinued treatment due to pleural effusion, In the ENESTnd study, pleural effusion occurred in a small number of nilotinib treated patients and was not reported in the single arm studies of nilotinib. Cardiac toxicity In 2006, a report was published describing ten indivi duals who developed severe congestive heart failure on imatinib treatment. Based on laboratory stu dies, the authors suggested that this effect could occur as a result of inhibition of physiologic ABL activity in cardiac tissue, Subsequent retrospective analyses estimated that the frequency of CHF or left ventricular dysfunction during imatinib therapy for CML was 0.<br><br> 5 1. 1%, In TKI studies, instances of QT prolongation were reported, In particular, in studies of nilotinib in patients with imatinib resistance or intolerance, sudden death was reported in 0. 6% of patients, with a similar rate of occurrence in an expanded access program. The timing of sudden death relative to initiation of nilotinib suggested that ventricular repolarization abnormalities may have contributed to their occurrence, In recent TKI trials, patients with significant cardiac disease were excluded from participating.